loading
Schlusskurs vom Vortag:
$3.76
Offen:
$3.8
24-Stunden-Volumen:
152.70K
Relative Volume:
0.54
Marktkapitalisierung:
$176.62M
Einnahmen:
$114.70K
Nettoeinkommen (Verlust:
$-37.06M
KGV:
-0.9291
EPS:
-3.9929
Netto-Cashflow:
$-30.69M
1W Leistung:
+0.27%
1M Leistung:
+15.94%
6M Leistung:
+98.40%
1J Leistung:
-12.71%
1-Tages-Spanne:
Value
$3.5065
$3.80
1-Wochen-Bereich:
Value
$3.30
$4.08
52-Wochen-Spanne:
Value
$1.00
$6.60

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Name
Firmenname
Sab Biotherapeutics Inc
Name
Telefon
305-845-2813
Name
Adresse
777 W 41ST ST, MIAMI BEACH
Name
Mitarbeiter
63
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
SABS's Discussions on Twitter

Vergleichen Sie SABS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SABS
Sab Biotherapeutics Inc
3.71 179.00M 114.70K -37.06M -30.69M -3.9929
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.64 110.88B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
726.21 72.79B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
890.11 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
404.46 54.85B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
189.85 41.41B 447.02M -1.18B -906.14M -6.1812

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-17 Eingeleitet Leerink Partners Outperform
2025-05-14 Fortgesetzt H.C. Wainwright Buy
2024-10-09 Eingeleitet Craig Hallum Buy
2024-08-28 Eingeleitet Oppenheimer Outperform
2021-11-05 Eingeleitet Chardan Capital Markets Buy

Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten

pulisher
Dec 08, 2025

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management - Investing News Network

Dec 08, 2025
pulisher
Dec 08, 2025

SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at ATTD-Asia Conference 2025 - Quiver Quantitative

Dec 08, 2025
pulisher
Dec 08, 2025

SAB BIO to Present Data Showcasing Progress in the - GlobeNewswire

Dec 08, 2025
pulisher
Dec 04, 2025

Institution Moves: Is Above Food Ingredients Inc. stock safe for conservative investorsNew Guidance & Technical Pattern Based Buy Signals - BỘ NỘI VỤ

Dec 04, 2025
pulisher
Dec 04, 2025

Why analysts upgrade SAB Biotherapeutics Inc. Equity Warrant stockQuarterly Portfolio Review & Safe Swing Trade Setups - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Will SAB Biotherapeutics Inc. Equity Warrant stock gain from lower inflationMarket Movers & Consistent Growth Equity Picks - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Dec 04, 2025
pulisher
Dec 04, 2025

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 04, 2025
pulisher
Dec 02, 2025

How SAB Biotherapeutics Inc. stock performs in rate cut cyclesWeekly Profit Report & AI Forecast Swing Trade Picks - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Will SAB Biotherapeutics Inc. Equity Warrant stock reach Wall Street targetsTrade Analysis Report & Daily Volume Surge Signals - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Is SAB Biotherapeutics Inc. Equity Warrant stock a buy before product launchesEarnings Overview Report & Daily Technical Stock Forecast Reports - Newser

Dec 02, 2025
pulisher
Nov 27, 2025

Weekly Recap: What margin trends mean for SAB Biotherapeutics Inc. stockMarket Performance Summary & Low Volatility Stock Recommendations - moha.gov.vn

Nov 27, 2025
pulisher
Nov 27, 2025

How SAB Biotherapeutics Inc. Equity Warrant stock trades before earnings2025 EndofYear Setup & Short-Term High Return Strategies - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 27, 2025

The growth track for SAB Biotherapeutics Inc (SABS) has changed recently - Setenews

Nov 27, 2025
pulisher
Nov 27, 2025

Will SAB Biotherapeutics Inc. stock benefit from green energy trendsEarnings Risk Summary & Accurate Entry/Exit Alerts - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 27, 2025

Leerink Partnrs Has Optimistic View of SABS FY2025 Earnings - MarketBeat

Nov 27, 2025
pulisher
Nov 27, 2025

Research Analysts Set Expectations for SABS FY2025 Earnings - Defense World

Nov 27, 2025
pulisher
Nov 26, 2025

Q1 Earnings Forecast for SABS Issued By Leerink Partnrs - Defense World

Nov 26, 2025
pulisher
Nov 25, 2025

SAB Biotherapeutics Inc Stock Analysis and ForecastEx-Dividend Date Alerts & Low Cost Stock Picks - earlytimes.in

Nov 25, 2025
pulisher
Nov 22, 2025

SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week - Yahoo Finance

Nov 22, 2025
pulisher
Nov 22, 2025

SABS Q4 EPS Forecast Lifted by Brookline Capital Management - Defense World

Nov 22, 2025
pulisher
Nov 21, 2025

SAB Biotherapeutics Inc. (SABS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 21, 2025
pulisher
Nov 21, 2025

What risks investors should watch in SAB Biotherapeutics Inc. stockQuarterly Trade Summary & AI Powered Market Entry Ideas - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Will SAB Biotherapeutics Inc. stock reach Wall Street targets2025 Valuation Update & Accurate Entry and Exit Point Alerts - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Trend analysis for SAB Biotherapeutics Inc. Equity Warrant this weekDollar Strength & AI Powered Market Entry Ideas - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Will SAB Biotherapeutics Inc. Equity Warrant stock outperform Dow Jones indexWeekly Volume Report & Growth Focused Investment Plans - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Is SAB Biotherapeutics Inc. forming a reversal patternJuly 2025 Big Picture & Accurate Intraday Trading Signals - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Why SAB Biotherapeutics Inc. stock remains a top recommendationBond Market & AI Based Buy/Sell Signal Reports - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Is SAB Biotherapeutics Inc. stock safe for conservative investors2025 Pullback Review & High Accuracy Trade Signal Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Using Bollinger Bands to evaluate SAB Biotherapeutics Inc. Equity WarrantRate Hike & Weekly Watchlist of Top Performers - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is SAB Biotherapeutics Inc. Equity Warrant reversing from oversold territoryAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will SAB Biotherapeutics Inc. stock deliver better than expected guidanceWeekly Investment Summary & Fast Exit and Entry Strategy Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What risks investors should watch in SAB Biotherapeutics Inc. Equity Warrant stockPortfolio Update Report & Reliable Price Breakout Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

SAB Biotherapeutics Reports Positive Q3 2025 Earnings - MSN

Nov 19, 2025
pulisher
Nov 19, 2025

SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap - TradingView

Nov 19, 2025
pulisher
Nov 19, 2025

What sentiment indicators say about SAB Biotherapeutics Inc. stock2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Can SAB Biotherapeutics Inc. Equity Warrant stock resist sector downturns2025 Top Decliners & AI Based Buy and Sell Signals - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Ranking SAB Biotherapeutics Inc. Equity Warrant among high performing stocks via tools2025 Earnings Surprises & Verified Entry Point Signals - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Why SAB Biotherapeutics Inc. Equity Warrant stock is considered a top pickJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is SAB Biotherapeutics Inc. Equity Warrant a candidate for recovery playJuly 2025 Spike Watch & Real-Time Chart Breakout Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Chardan Capital Reiterates “Buy” Rating for SAB Biotherapeutics (NASDAQ:SABS) - Defense World

Nov 19, 2025

Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.26
price up icon 0.45%
$95.17
price up icon 0.01%
$31.24
price up icon 1.00%
$95.73
price down icon 0.12%
biotechnology ONC
$322.68
price up icon 1.25%
$189.85
price down icon 2.22%
Kapitalisierung:     |  Volumen (24h):